AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 SEP 1 - (NewsRx.com & NewsRx.net) -- Alzheimer vaccines must be thoroughly tested in non-murine animal models before trials begin in humans.
According to a study from Australia and the United States, "Recent clinical and neuropathological data show that the AN 1792 vaccine enhanced the production of A-beta antibodies in the sera of Alzheimer disease (AD) patients, but it appears to have been ineffective at stimulating the removal of A-beta deposits from the brain or at slowing the rate of cognitive decline. The 19 cases of meningoencephalitis were not linked in an obvious way to serum antibody titer, but they may have been linked to infiltration of the brain by antibodies and/or T-cells. Brain imaging indicated that edema associated with the neuroinflammation did not reflect the typical distribution of neuritic plaques in AD."
"These outcomes were not anticipated by experiments on transgenic mice because compared to humans, these mice have less genetic variability, and their plaques have a different chemical composition, making them far more soluble and easier to remove," said Stephen R. Robinson and collaborators at Monash University and James Cook University in Australia and Case Western Reserve University in the U.S. "Furthermore, the consequences of vaccination are different. Vaccination of transgenic mice removes superfluous human A-beta while ...